Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 3 years
- Director since
- 2023
3 years of board service in total across 1 board, counting each seat separately. Longest: Quince Therapeutics Inc., 3 years.
Quince Therapeutics Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 18, 2026 | Exelixis Inc. | Open-market sale | −34,901 | $50.00 | $1,745,050 |
| May 15, 2026 | Exelixis Inc. | Shares withheld for tax | −40,892 | $51.10 | $2,089,581 |
| Feb 26, 2026 | Exelixis Inc. | Grant or award | +52,018 | — | — |
| Feb 17, 2026 | Exelixis Inc. | Open-market sale | −30,617 | $43.67 | $1,337,044 |
| Feb 15, 2026 | Exelixis Inc. | Shares withheld for tax | −35,870 | $43.92 | $1,575,410 |
| Feb 13, 2026 | Exelixis Inc. | Open-market sale | −34,278 | $43.00 | $1,473,954 |
| Jan 15, 2026 | Exelixis Inc. | Grant or award | +149,474 | — | — |
| Jan 15, 2026 | Exelixis Inc. | Shares withheld for tax | −40,459 | $45.23 | $1,829,961 |
| May 16, 2025 | Exelixis Inc. | Option exercise | +100,000 | $18.80 | $1,880,000 |
| May 16, 2025 | Exelixis Inc. | Open-market sale | −100,000 | $46.00 | $4,600,000 |
| May 15, 2025 | Exelixis Inc. | Shares withheld for tax | −41,422 | $44.65 | $1,849,492 |
| Mar 31, 2025 | Exelixis Inc. | Grant or award | +170,009 | — | — |
| Feb 26, 2025 | Exelixis Inc. | Grant or award | +59,648 | — | — |
| Feb 24, 2025 | Exelixis Inc. | Option exercise | +29,314 | $18.80 | $551,103 |
| Feb 24, 2025 | Exelixis Inc. | Open-market sale | −29,314 | $36.14 | $1,059,408 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.